CANADA LIFE ASSURANCE Co Sells 5,331 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CANADA LIFE ASSURANCE Co trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 120,865 shares of the biopharmaceutical company’s stock after selling 5,331 shares during the quarter. CANADA LIFE ASSURANCE Co’s holdings in Regeneron Pharmaceuticals were worth $86,049,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Virtu Financial LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $6,364,000. Morse Asset Management Inc increased its stake in shares of Regeneron Pharmaceuticals by 0.9% in the 3rd quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company’s stock valued at $5,053,000 after purchasing an additional 43 shares during the last quarter. Anchor Investment Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 212.0% during the 3rd quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 583 shares in the last quarter. Sculati Wealth Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 1.9% during the 3rd quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company’s stock worth $1,970,000 after buying an additional 38 shares during the last quarter. Finally, Pine Valley Investments Ltd Liability Co boosted its stake in Regeneron Pharmaceuticals by 19.0% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company’s stock valued at $5,575,000 after buying an additional 848 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 2.5 %

NASDAQ:REGN opened at $563.16 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $525.99 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm’s fifty day moving average is $647.99 and its 200-day moving average is $743.86. The firm has a market cap of $61.57 billion, a P/E ratio of 14.71, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the firm posted $11.86 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.63%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analysts Set New Price Targets

REGN has been the subject of several research analyst reports. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Bank of America lowered their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research report on Thursday. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research report on Monday, March 31st. The Goldman Sachs Group decreased their target price on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $963.56.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.